BioAffinity Technologies closed a registered direct financing on October 9, 2026, raising approximately $4 million in gross proceeds. The company issued 116,545 shares of common stock and pre-funded warrants for 536,836 shares at $6.122 and $6.115 per unit, respectively. Concurrently, it sold unregistered warrants to purchase up to 980,072 shares at an exercise price of $6.122, exercisable five years after stockholder approval. Net proceeds will support working capital and sales growth for its CyPath Lung diagnostic test.
